Our data suggest that targeting RNF5 and HDAC pathways represents a therapeutic modality for AML and that RNF5 or RBBP4 abundance could serve as a prognostic marker and means to stratify patients for treatment with HDAC inhibitors. This evidence concerns the gene HDAC9 and acute myeloid leukemia.